Purified myelin proteolipid protein (PLP) for PLP-induced EAE models in mouse and rat. 

Multiple Sclerosis (MS) is a demyelinating disease of the central nervous system (CNS). The main characteristics of the disease are focal areas of demyelination and inflammation, however the pathogenesis is unclear.

Although no animal model thus far establishes all facets of human MS, Experimental Autoimmune Encephalomyelitis (EAE) represents the model most studied for the disease. Initially brain homogenates were used as antigens for immunization. Today, myelin related proteins or peptides are used in the disease.

References/Citations: 

Hansson, C., Lebrero-Fernández, C., Schön, K., Angeletti, D., & Lycke, N. (2023). Tr1 cell-mediated protection against autoimmune disease by intranasal administration of a fusion protein targeting cDC1 cells. Mucosal Immunology.

The novel small molecule drug Rabeximod is effective in reducing disease severity of mouse models of autoimmune disorders
M Hultqvist, K S Nandakumar, U Björklund, and R Holmdahl Ann Rheum Dis, Jan 2009; 68: 130 - 135.